Samsung Biologics is a fully integrated CDMO headquartered in Incheon, South Korea, that provides end-to-end development and manufacturing services for biologics and mRNA-based therapeutics and vaccines. Established in 2011, the company offers cell line and process development, analytical services, GMP clinical and commercial manufacturing of drug substance and drug product, as well as integrated QC testing, storage, and regulatory support. Samsung Biologics serves partners worldwide with scalable, one-stop solutions from discovery through commercialization. Current capacity of 784,000 L makes the Incheon campus among the world's largest biomanufacturing sites.
